Abstract：
UNASSIGNED: Studies have compared chimeric antigen receptor (CAR) T-cell therapies and salvage chemotherapy in relapsed/refractory large B-cell lymphoma (LBCL) patients, but further evidence of their relative effectiveness is warranted.
UNASSIGNED: Our systematic review identified studies comparing efficacy and safety outcomes of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) trials to salvage chemotherapy cohorts in LBCL patients with ≥2 prior lines of treatment; and an extended evidence network included indirect comparisons comparing CAR T-cell therapies. We conducted network meta-analyzes using Bayesian hierarchical modeling.
UNASSIGNED: Three studies comparing ZUMA-1 (axi-cel), TRANSCEND (liso-cel) and JULIET (tisa-cel) trials to salvage chemotherapy within the SCHOLAR-1 cohort were identified. Axi-cel (odds ratio [OR]:5.63; 95% credible interval [CrI]:2.66-12.42) and liso-cel (OR:4.26; 95%CrI:2.33-7.93) showed a significant increased overall response rate compared to tisa-cel, but not to one-another. Axi-cel demonstrated significant improvements in overall survival relative to liso-cel (hazard ratio [HR]:0.54; 95%CrI:0.37-0.79) and tisa-cel (HR:0.47; 95%CrI:0.26-0.88). Higher rates of grade ≥3 neurological events were observed with axi-cel than with tisa-cel and liso-cel.
UNASSIGNED: We highlight important differences in clinical outcomes between CAR T-cell therapies. Axi-cel demonstrated improved overall survival compared to tisa-cel and liso-cel, and both axi-cel and liso-cel showed higher response rates compared to tisa-cel.
UNASSIGNED: Our systematic review identified studies comparing efficacy and safety outcomes of axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel) and tisagenlecleucel (tisa-cel) trials to salvage chemotherapy cohorts in LBCL patients with ≥2 prior lines of treatment; and an extended evidence network included indirect comparisons comparing CAR T-cell therapies. We conducted network meta-analyzes using Bayesian hierarchical modeling.
UNASSIGNED: Three studies comparing ZUMA-1 (axi-cel), TRANSCEND (liso-cel) and JULIET (tisa-cel) trials to salvage chemotherapy within the SCHOLAR-1 cohort were identified. Axi-cel (odds ratio [OR]:5.63; 95% credible interval [CrI]:2.66-12.42) and liso-cel (OR:4.26; 95%CrI:2.33-7.93) showed a significant increased overall response rate compared to tisa-cel, but not to one-another. Axi-cel demonstrated significant improvements in overall survival relative to liso-cel (hazard ratio [HR]:0.54; 95%CrI:0.37-0.79) and tisa-cel (HR:0.47; 95%CrI:0.26-0.88). Higher rates of grade ≥3 neurological events were observed with axi-cel than with tisa-cel and liso-cel.
UNASSIGNED: We highlight important differences in clinical outcomes between CAR T-cell therapies. Axi-cel demonstrated improved overall survival compared to tisa-cel and liso-cel, and both axi-cel and liso-cel showed higher response rates compared to tisa-cel.
摘要：
■研究比较了复发性/难治性大B细胞淋巴瘤（LBCL）患者的嵌合抗原受体（CAR）T细胞疗法和挽救性化疗，但有必要进一步证明其相对有效性.
■我们的系统评价确定了比较axicabtageneciloleucel（axi-cel）疗效和安全性结果的研究，lisocabtagenemaraleucel(liso-cel)和tisagenlecleucel(tisa-cel)试验用于挽救LBCL患者的化疗队列,这些患者先前有≥2行治疗;扩展的证据网络包括间接比较CAR-T细胞治疗.我们使用贝叶斯分层建模进行了网络元分析。
■三项比较ZUMA-1(axi-cel)的研究，确定了在SCHOLAR-1队列中挽救化疗的TRANSCEND（liso-cel）和JULIET（tisa-cel）试验。Axi-cel（比值比[OR]：5.63;95％可信区间[CrI]：2.66-12.42）和liso-cel（OR：4.26;95％CrI：2.33-7.93）显示出与tisa-cel相比，总体反应率显着增加，但不是彼此。Axi-cel相对于liso-cel（风险比[HR]：0.54;95％CrI：0.37-0.79）和tisa-cel（HR：0.47;95％CrI：0.26-0.88）显示出总生存期的显着改善。axi-cel的≥3级神经系统事件发生率高于tisa-cel和liso-cel。
■我们强调了CAR-T细胞疗法在临床结果上的重要差异。与tisa-cel和liso-cel相比，Axi-cel表现出改善的总体生存率，与tisa-cel相比，axi-cel和liso-cel均显示出更高的应答率。
■我们的系统评价确定了比较axicabtageneciloleucel（axi-cel）疗效和安全性结果的研究，lisocabtagenemaraleucel(liso-cel)和tisagenlecleucel(tisa-cel)试验用于挽救LBCL患者的化疗队列,这些患者先前有≥2行治疗;扩展的证据网络包括间接比较CAR-T细胞治疗.我们使用贝叶斯分层建模进行了网络元分析。
■三项比较ZUMA-1(axi-cel)的研究，确定了在SCHOLAR-1队列中挽救化疗的TRANSCEND（liso-cel）和JULIET（tisa-cel）试验。Axi-cel（比值比[OR]：5.63;95％可信区间[CrI]：2.66-12.42）和liso-cel（OR：4.26;95％CrI：2.33-7.93）显示出与tisa-cel相比，总体反应率显着增加，但不是彼此。Axi-cel相对于liso-cel（风险比[HR]：0.54;95％CrI：0.37-0.79）和tisa-cel（HR：0.47;95％CrI：0.26-0.88）显示出总生存期的显着改善。axi-cel的≥3级神经系统事件发生率高于tisa-cel和liso-cel。
■我们强调了CAR-T细胞疗法在临床结果上的重要差异。与tisa-cel和liso-cel相比，Axi-cel表现出改善的总体生存率，与tisa-cel相比，axi-cel和liso-cel均显示出更高的应答率。
